HCA Healthcare LewisGale Medical Center Gastroenterology

Topics

• Hepatitis C virus research 181
• Liver Disease Diagnosis and Treatment 34
• Liver Disease and Transplantation 31
• Liver Diseases and Immunity 19
• Organ Transplantation Techniques and Outcomes 17
• Hepatitis B Virus Studies 11
• Gallbladder and Bile Duct Disorders 7
• Hepatocellular Carcinoma Treatment and Prognosis 7
• Drug Transport and Resistance Mechanisms 4
• Platelet Disorders and Treatments 4
• Cholangiocarcinoma and Gallbladder Cancer Studies 3
• Renal Transplantation Outcomes and Treatments 3

Most cited

1. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.

   The New England journal of medicine · 2024 · 257 citations · Mitchell Shiffman

2. Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial.

   Journal of hepatology · 2026 · 24 citations · Mitchell Shiffman

3. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.

   Hepatology (Baltimore, Md.) · 2021 · 250 citations · Mitchell Shiffman

4. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.

   Hepatology (Baltimore, Md.) · 2023 · 108 citations · Mitchell Shiffman

5. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.

   Journal of hepatology · 2022 · 72 citations · Mitchell Shiffman

6. Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.

   Alimentary pharmacology & therapeutics · 2024 · 36 citations · Mitchell Shiffman